The Critical Role of Prior Authorization Committees in Canada
In this blog, we focus on the important role of Drug Review Committees in maintaining a responsive and sustainable PA process through a regular review of existing medications as well as reviewing new medications that may be subject to prior authorization.
Answering Your FAQs on Prior Authorization Initiatives You Have Seen
The interest in prior authorization is growing, which is driving more interest in reforming current practices and policies to become more efficient and drive down administration costs and reduce the time-consuming claims process.
Modernization Efforts in Prior Authorization
In this podcast Ramy El-Kholi, Chief Commercial Officer with OkRx joins Denise Balch to provide an update on the development of electronic prior authorization (ePA) and its implementation in Canada.
Prior Authorization in Canada: The Role of Transparency and Communication
Navigate the prior authorization (PA) process in Canada can be time consuming and confusing. Inefficiencies in the system create real challenges for all stakeholders—physicians, pharmacists, insurers, advisors, and most importantly, patients.
Do Patient Support Programs Just Give Away Free Drugs?
Patient Support Programs (PSPs) may secure alternate funding from pharmaceutical manufacturers when there are reimbursement gaps, but that is just one role.
When Changing Carriers Can Be Risky
Did you know that changing group insurance carriers can result in loss of access to specialty medications for plan members? This can happen even when a plan member’s claim has been approved through prior authorization with the old carrier, usually for twelve months, and there are no changes to the drug plan formulary with the new carrier.
New Developments in Prior Authorization and Specialty Drugs
The Prior Authorization Framework and Accreditation (PAFA) Program is an exciting new development in the Canadian specialty drug landscape that will benefit patients, plan sponsors, and other industry stakeholders, including payers.
Recap – What’s Happening on Prior Authorization
As we prepare to announce details of a new phase of prior authorization for specialty drug claims later this summer, now is a good time to recap our journey as well as next steps.
Significant Grant Awarded for Development of Electronic Prior Authorization in Canada
GreenShield and OkRx, a technology solutions provider, have been awarded a grant from the Canadian Medical Association (CMA) Foundation, Scotiabank, and MD Financial Group for the launch of electronic prior authorization (ePA) in Canada.
A Rheumatologist’s Perspective on Prior Authorization and Timely Access to Treatments
Featuring Dr. Imtiaz Khan, licensed rheumatologist in Canada and the U.S. and Chair of the Ontario Rheumatologists Association (ORA) Private Payers committee.